**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 5728**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (5): Colorectal cancer

**Different standards for healthy screenees than patients in routine clinics?**

Hoff G. Quality in screening and clinics

Geir Hoff

**Geir Hoff,** Department of Research and Development, Telemark Hospital, 3710 Skien, Norway

**Geir Hoff,** Cancer Registry of Norway, 0369 Oslo, Norway

**Geir Hoff,** Institute of Health and Society, University of Oslo, 0850 Oslo, Norway

**Author contributions**: Hoff G solely contributed to this manuscript.

**Correspondence to: Geir Hoff, MD, PhD, Professor,** Department of Research and Development, Telemark Hospital, Bjørnstjerne Bjørnsons Gate 6, 3710 Skien, Norway. hofg@online.no

**Telephone:** +47-91-866762  **Fax:** +47-22-451370

**Received:** September 23, 2013  **Revised:** October 20, 2013

**Accepted:** November 3, 2013

**Published online:**

**Abstract**

Less than 5% of colorectal adenomas will become malignant, but we do not have sufficient knowledge about their natural course to target removal of these 5% only. Thus, 95% of polypectomies are a waste of time exposing patients to a small risk of complications. Recently, a new type of polyps, sessile serrated polyps, has attracted attention. Previously considered innocuous, they are now found to have molecular similarities to cancer and some guidelines recommend to have them removed. These lesions are often flat, covered by mucous, not easily seen and situated in the proximal colon where the bowel wall is thinner. Thus, polypectomy carries a higher risk of perforation than predominantly left-sided, stalked adenomas – and we do not know what is gained in terms of cancer prevention. Screening is a neat balance between harms and benefit for presumptively healthy participants not interested in risk exposure to obtain confirmation of being healthy. The situation is quite different for patient worried about symptom. Thus, the standards set for evidence-based practice may be higher for screening than for routine clinics – a mechanism which may benefit patients in the long run.

© 2013 Baishideng. All rights reserved.

**Key words:** Colonoscopy; Screening; Quality assurance; Standards

**Core tip:** There is a basic difference in incitements to attend for screening when you are healthy and for routine clinics when you are ill. This article points out logical mechanisms which may set standards for screening higher than for routine clinics, but this may prove to be of benefit for clinical services and patients in the long run. This is highlighted by sessile serrated polyps which were previously classified as innocuous hyperplastic polyps. Recent guidelines now recommend polypectomy of these lesions for cancer prevention, but we do not know the benefit gained – only the increased risk of perforation by polypectomy.

Hoff G. Different standards for healthy screenees than patients in routine clinics? *World J Gastroenterol* 2013;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v19.i0.0000

**MECHANISMS FAVOURING DIFFERENT STANDARDS**

We know that there are endoscopist-dependent variations in colonoscopy performance – whether this service is provided in routine clinics or screening[[1-4](#_ENREF_1)]. Quality assurance (QA) initiatives driven by health care providers may be half-hearted – particularly when demands for colonoscopy outnumber available capacity and reducing unacceptable waiting lists is first priority. Within the European Union, however, it has been stated explicitly for screening that only organized screening that can be evaluated is to be accepted, “performance indicators should be monitored regularly” and the population should be protected from “poor-quality screening”[[5](#_ENREF_5)]. Independent of such policy statements for QA which may have its counterparts in clinical non-screening services in many countries, client or patient-driven QA may have a stronger impact in screening programmes than in routine clinics. The option of not attending if the quality is sub-standard is both more realistic and a dreadful threat to screening programmes compared to routine clinical services. Whichever CRC screening method is used, high attendance rates are crucial for the success of any screening programme - “the best screening test is the one that gets done”[6].

There is a basic difference between screening participants and patients. Screenees are presumptively healthy individuals who seek confirmation that they are just that – healthy. Patients have symptoms and disease for which they seek whatever help may be offered. This means that patients may be more willing to accept some risk of complications, harms and discomfort to be cured. It is reasonable that screenees are not willing to subject themselves to risks and discomfort to obtain confirmation of being healthy.

***Screening participants***

Presumptively healthy seeking confirmation of being healthy. Not willing to take risks to obtain this confirmation. They request documentation of benefits and harms – “what is in it for me?”

***Patients***

They have symptoms or known disease for which they seek whatever help they may be offered. It may be a matter of clinging to a hope of cure with great willingness to pay and few questions asked on documentation of effect – “please, just do something!”

 Since high attendance rates are crucial for screening programmes, it is important to understand the reasons for non-attendance. This is far from a primary issue in routine clinics serving patients. In focus groups addressing CRC screening, both representatives of target populations and family doctors have expressed scepticism to screening, questioning the evidence of its effectiveness[7]. To meet these critics, facts about risks and benefits and defining fields of uncertainty must be produced and made accessible in a trustworthy and understandable format to provide a basis for informed decision-making by members of the target population[8,9]. This is quite a different exercise from campaigning for screening by appealing to fear, guilt and personal responsibility – methods that may have been used too frequently in the short history of screening to improve attendance[10]. Such campaigning will only tear down any trustworthiness there may have been. There should be a strong incitement to provide high-degree level of evidence to support (or discard) screening – evidence that can withstand scepticism and critics generated by poor-level evidence and over-selling screening services[10].

**SIZE OF THE PROBLEM AND THE HIGH INTENTIONS OF DOING GOOD**

On a worldwide basis, there are more than 1.2 million new cases of colorectal cancer (CRC) diagnosed annually with prospects of 5-year survival for 50%-60% of patients[11,12]. Symptoms often appear late and they are unspecific – mimicking common and more trivial conditions like haemorrhoids and irritable bowel. Although progress is being made on treatment of advanced CRC, new drugs are driving costs although the best bet for cure remains early diagnosis and surgery. Both to get at the cancer at an early, asymptomatic stage to save lives and suffering - and to save costs for treatment of advanced disease[13], CRC screening is recommended in several countries[14]. There are several screening methods, but only fecal occult blood tests (FOBT) and flexible sigmoidoscopy (FS) have been subjected to randomized trials (RCT) with long-term follow-up[15-18]. By intention-to-treat analyses, FOBT screening reduces CRC mortality by 15%-18% with no effect on CRC incidence. FS screening reduces mortality by 28% and incidence by 18%[18]. Intuitively, colonoscopy screening should be twice as good as FS (“half-way colonoscopy”) combining “gold standard” sensitivity for CRC and polyp detection with tissue sampling and removal of CRC precursor lesions (polyps). There are RCTs on colonoscopy underway, but results are not expected for many years[19,20]. Retrospective studies, however, have suggested that colonoscopy screening may not be as effective as expected in reducing right-sided CRC[21]. It has been suggested that right-sided (proximal) sessile serrated polyps, which are easily overlooked and share molecular similarities to CRC, may represent an additional polyp-carcinoma pathway similar to the traditional adenoma-carcinoma pathway[22]. This may explain poorer results than expected for colonoscopy in reducing the burden of right-sided CRC. When the trials on FOBT and FS screening were done, endoscopists and pathologists largely considered sessile serrated polyps to be hyperplastic and non-neoplastic with no intrinsic potential to develop into CRC. Changing to go aggressively for these right-sided sessile lesion has its implications (*e.g.*, higher risk of perforation at polypectomy) and we really do not know what there is to be gained – *i.e.,* we cannot quantify expectations of a reduced risk of CRC.

**OVERTREATMENT WITH A FEAR OF NOT DOING ENOUGH**

Screening is a neat balance between benefits and harms - benefit for the few (those few discovered to have asymptomatic CRC or advanced adenoma) versus inconvenience and potential risks for the many (all other participants). Providing data on CRC mortality and/or incidence reduction is a prerequisite before implementing screening programmes[5], but the target population should also receive valid information on the downsides of screening, like the risk of perforation and bleeding when polypectomy is recommended. We now have long-term results from RCTs on FOBT and FS screening based on the standards used in the trials, including work-up colonoscopies and surgical treatment, and we can provide the target population with information of what is to be gained in terms of mortality and incidence reduction and the risks involved with endoscopy, polyp removal and surgery when required. This is very much a satisfactory level of practicing “evidence-based medicine”.

Our current practice of polyp treatment and surveillance is largely based on consensus guidelines. If we change our practice in screening programmes from the standards used in trials preceding the programmes, we do this because we believe such adjustments are for the good. The intentions may be the best, but is the evidence up to standards required for the target population to feel it worthwhile attending for screening? RCTs on FS screening give 18% reduced risk of CRC with a 0.04% risk of perforation and 0.1% risk of perforation at work-up colonoscopy[18]. But – more meticulous search and removal of proximal sessile serrated polyps may involve a risk of 3% for severe complications (perforation and bleeding) for these lesions[23] with no evidence of what to be gained (Figure 1). This is a level of uncertainty that may not be questioned by patients, but more likely tilt the decision of the potential screenee towards not attending.

Overdiagnosis and overtreatment of cancer is a recent issue that has emerged from screening activity – not from routine clinical work[24]. For CRC, we know that more than 95% of polypectomies are a waste of time involving unnecessary risks, but we do not know which 5% to go for. After more than 120 years of the adenoma-carcinoma sequence theory[25], we do not know the natural history of adenomas. We can say very little about future risk of CRC in a polypectomized adenoma – had it not been removed. It is desirable with better definition and targeting of high-risk polyps to be removed and low-risk lesions to be ignored at colonoscopy. It is hard to see how this knowledge-gap can be filled without accepting prospective studies on in-situ polyps. With a low risk for complications at polypectomy, this may not be acceptable. Moving towards more aggressive interventions without knowing the magnitude of expected benefit, we may eventually reach a line when screening either is to be stopped or modified due to complications. At that point in time the problems of overtreatment may become so pronounced that in-situ research with all possible security measures may be accepted. There may be more at stake for screening programme providers and participants (screenees) on this issue than for patients, and it may be that comparative effectiveness research (CER) within screening programmes[26] may provide possibilities to fill this and other knowledge-gaps – also for the benefit of clinical practice. Among 45 original publications on the main study and sub-studies published so far from the Norwegian Colorectal Cancer Prevention trial (NORCCAP) there were several findings of transfer value to routine clinical practice – particularly on endoscopy technique and technology (listed in [www.kreftregisteret.no/norccap](http://www.kreftregisteret.no/norccap)).

**CONCLUSION**

There is a basic difference in incitements to attend for screening when you are healthy and for routine clinics when you are ill. This may be more clearly brought forward by an increasing demand for patients and clients to have a say in quality assurance of health care provisions – both in screening and routine clinics. There are logical mechanisms which may set standards for screening higher than for routine clinics, but this may prove to be of benefit for clinical services and patients in the long run.

**REFERENCES**

1 **Hoff G**, Bretthauer M, Huppertz-Hauss G, Kittang E, Stallemo A, Høie O, Dahler S, Nyhus S, Halvorsen FA, Pallenschat J, Vetvik K, Kristian Sandvei P, Friestad J, Pytte R, Coll P. The Norwegian Gastronet project: Continuous quality improvement of colonoscopy in 14 Norwegian centres. *Scand J Gastroenterol* 2006; **41**: 481-487 [PMID: 16635918 DOI: 10.1080/00365520500265208]

2 **Pinsky PF**, Schoen RE, Weissfeld JL, Kramer B, Hayes RB, Yokochi L. Variability in flexible sigmoidoscopy performance among examiners in a screening trial. *Clin Gastroenterol Hepatol* 2005; **3**: 792-797 [PMID: 16234008 DOI: 10.1053/S1542-3565(05)00286-7]

3 **Imperiali G**, Minoli G, Meucci GM, Spinzi G, Strocchi E, Terruzzi V, Radaelli F. Effectiveness of a continuous quality improvement program on colonoscopy practice. *Endoscopy* 2007; **39**: 314-318 [PMID: 17273959 DOI: 10.1055/s-2006-945196]

4 **Adler A**, Wegscheider K, Lieberman D, Aminalai A, Aschenbeck J, Drossel R, Mayr M, Mroß M, Scheel M, Schröder A, Gerber K, Stange G, Roll S, Gauger U, Wiedenmann B, Altenhofen L, Rosch T. Factors determining the quality of screening colonoscopy: a prospective study on adenoma detection rates, from 12,134 examinations (Berlin colonoscopy project 3, BECOP-3). *Gut* 2013; **62**: 236-241 [PMID: 22442161 DOI: 10.1136/gutjnl-2011-300167]

5 **EU Commission.** Council recommendation on cancer screening. Available from: URL: http: //ec.europa.eu/health/ph\_determinants/genetics/documents/com\_2003\_0230\_en.pdf. 2003.

6 **Winawer SJ**. The multidisciplinary management of gastrointestinal cancer. Colorectal cancer screening. *Best Pract Res Clin Gastroenterol* 2007; **21**: 1031-1048 [PMID: 18070702 DOI: 10.1016/j.bpg.2007.09.004]

7 **Goel V**, Gray R, Chart P, Fitch M, Saibil F, Zdanowicz Y. Perspectives on colorectal cancer screening: a focus group study. *Health Expect* 2004; **7**: 51-60 [PMID: 14982499 DOI: 10.1046/j.1369-6513.2003.00252.x]

8 **Greisinger A**, Hawley ST, Bettencourt JL, Perz CA, Vernon SW. Primary care patients' understanding of colorectal cancer screening. *Cancer Detect Prev* 2006; **30**: 67-74 [PMID: 16458449 DOI: 10.1016/j.cdp.2005.10.001]

9 **Ekelund G**, Manjer J, Zackrisson S. Population-based screening for colorectal cancer with faecal occult blood test--do we really have enough evidence? *Int J Colorectal Dis* 2010; **25**: 1269-1275 [PMID: 20676659 DOI: 10.1007/s00384-010-1027-1]

10 **Woloshin S**, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns--getting past uninformative persuasion. *N Engl J Med* 2012; **367**: 1677-1679 [PMID: 23113476 DOI: 10.1056/NEJMp1209407]

11 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

12 **Ferlay J**, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer* 2010; **46**: 765-781 [PMID: 20116997 DOI: 10.1016/j.ejca.2009.12.014]

13 **Sieg A**, Brenner H. Cost-saving analysis of screening colonoscopy in Germany. *Z Gastroenterol* 2007; **45**: 945-951 [PMID: 17874356 DOI: 10.1055/s-2007-963435]

14 **Benson VS**, Patnick J, Davies AK, Nadel MR, Smith RA, Atkin WS. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. *Int J Cancer* 2008; **122**: 1357-1367 [PMID: 18033685 DOI: 10.1002/ijc.23273]

15 **Mandel JS**, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med* 2000; **343**: 1603-1607 [PMID: 11096167 DOI: 10.1056/NEJM200011303432203]

16 **Kronborg O**, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet* 1996; **348**: 1467-1471 [PMID: 8942774 DOI: 10.1016/S0140-6736(96)03430-7]

17 **Hardcastle JD**, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet* 1996; **348**: 1472-1477 [PMID: 8942775 DOI: 10.1016/S0140-6736(96)03386-7]

18 **Elmunzer BJ**, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2012; **9**: e1001352 [PMID: 23226108 DOI: 10.1371/journal.pmed.1001352]

19 **Kaminski MF**, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooijen M, Regula J, van Leerdam M, Stefansson T, Påhlman L, Dekker E, Hernán MA, Garborg K, Hoff G. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. *Endoscopy* 2012; **44**: 695-702 [PMID: 22723185 DOI: 10.1055/s-0032-1306895]

20 **Quintero E**, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. *N Engl J Med* 2012; **366**: 697-706 [PMID: 22356323 DOI: 10.1056/NEJMoa1108895]

21 **Baxter NN**, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med* 2009; **150**: 1-8 [PMID: 19075198 DOI: 0000605-200901060-00306]

22 **Rex DK**, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, Kalady MF, O'Brien MJ, Odze RD, Ogino S, Parry S, Snover DC, Torlakovic EE, Wise PE, Young J, Church J. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol* 2012; **107**: 1315-129; quiz 1314, 1330 [PMID: 22710576 DOI: 10.1038/ajg.2012.161]

23 **Heldwein W**, Dollhopf M, Rösch T, Meining A, Schmidtsdorff G, Hasford J, Hermanek P, Burlefinger R, Birkner B, Schmitt W. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. *Endoscopy* 2005; **37**: 1116-1122 [PMID: 16281142 DOI: 10.1055/s-2005-870512]

24 **Esserman LJ**, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. *JAMA* 2013; **310**: 797-798 [PMID: 23896967 DOI: 10.1001/jama.2013.108415]

25 **Esmarch F**. Die Krankheiten des Mastdarmes und des Afters. Deutsche Chirurgie 1887; Stuttgart, Ferdinand Enke, 1887: Bd 48

26 **Bretthauer M**, Hoff G. Comparative effectiveness research in cancer screening programmes. *BMJ* 2012; **344**: e2864 [PMID: 22628002 DOI: 10.1136/bmj.e2864]

27 **Panteris V**, Haringsma J, Kuipers EJ. Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. *Endoscopy* 2009; **41**: 941-951 [PMID: 19866393 DOI: 10.1055/s-0029-1215179]

**P-Reviewers:** Amin AI, de Bree E, Meshikhes AWN, Rutegard J **S-Editor:** Gou SX  **L-Editor: E-Editor:**

**Figure 1** **Overtreatment with a fear of not doing enough.** Introducing uncertainty in the balance between benefits and harms of flexible sigmoidoscopy (FS) screening by adding systematic removal of proximal sessile serrated polyps (SSP) associated with 3% risk of perforation for these lesions[[23](#_ENREF_23)] and unknown benefit compared to 0.1% risk of perforation[[27](#_ENREF_27)] and known benefit.

